netFormulary North of Tyne and Gateshead Area Prescribing Committee NHS
Formulary  
 Search
 Formulary Chapter 8: Malignant disease and immunosuppression - Full Chapter
08.01.05  Expand sub section  Other antineoplastic drugs
Atezolizumab
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
NHS England
  • 1200mg/20mL concentrate for solution for infusion
  • Approved for treating locally advanced or metastatic non-small-cell lung cancer (NSCLC) in adults who have had chemotherapy (and targeted treatment if they have an EGFR- or ALK‑positive tumour). CDF
  • Approved for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma after disease progression following one prior platinum-containing chemotherapy regimen. CDF 
 
   
Carfilzomib (Kyprolis®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
NHS England
  • 10mg, 30mg & 60mg powder for solution for infusion
  • Approved for use in previously treated multiple myeloma in line with NICE and NHSE Commissioning Policy
 
Link  NICE TA457 Carfilzomib for previously treated multiple myeloma
   
Cytotoxic Drug Eribulin (Halaven®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
  • Approved for the treatment of locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens  in accordance with NICE and NHS England Commissioning Policy
 
Link  NICE TA423: Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens
   
Idelalisib
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
NHS England
  • Approved in combination with rituximab for the treatment of:
    • Untreated chronic lymphocytic leukaemia in adults with a 17p deletion or TP53 mutation; NICE or
    • Chronic lympocytic leukaemia in adults when the disease has been
      treated but has relapsed within 24 months NICE.
 
Link  NICE TA359: Chronic lymphocytic leukaemia - Idelalisib
   
Nivolumab
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
  • For the treatment of locally advanced or metastatic squamous nonsmall cell lung cancer (NSCLC) after prior chemotherapy in adults.
  • Approved for the treatment of advanced (unresectable or metastatic) melanoma in adults in line with NICE.
  • Approved in combination with ipilimumab for treating advanced melanoma in line with NICE and NHS England Commissioning Policy (SSC1664)
  • Approved for the treatment of advanced renal cell carcinoma in adults in line with NICE and NHS England Commissioning Policy
  • Approved for the treatment of relapsed of refractory classical Hodgkin lymphoma in line with NICE and NHS England Commissioning Policy 
 
Link  NICE TA384: Nivolumab for treating advanced (unresectable or metastatic) melanoma
Link  NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma
Link  NICE TA417: Nivolumab for previously treated advanced renal cell carcinoma
Link  NICE TA462 Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma
   
Olaparib 50mg capsules
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
NHS England
  • Approved for the maintenance treatment of BRCA 1 or 2 mutated, relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer in people whose relapsed disease has responded to platinum-based chemotherapy in line with NICE.
 
Link  NICE TA381: Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy
   
Olaratumab (Lartuvo®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
  • 10 mg/mL concentrate for solution for infusion
  • Approved for the treatment of advanced soft tissue sarcoma in combination with doxorubicin in line with NICE
 
Link  NICE TA465 Olaratumab in combination with doxorubicin for treating advanced soft tissue sarcoma
   
Cytotoxic Drug Panobinostat
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
  • Approved in combination with bortezomib and dexamethasone as an option for the treatment of multiple myeloma in line with NICE.
 
Link  NICE TA380: Panobinostat for treating multiple myeloma after at least 2 previous treatments
   
Pembrolizumab
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
  • Approved for the treatment of advanced melanoma after disease
    progression with ipilimumab in accordance with NICE. 
  • Approved for the treatment of advanced melanoma not previously treated with ipilimumab in accordance with NICE.
  • Approved for treating PD-L1-positive non-small-cell lung cancer
 
Link  NICE TA357: Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab
Link  NICE TA366: Pembrolizumab for advanced melanoma not previously treated with ipilimumab
Link  NICE TA428: Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy
   
Cytotoxic Drug Talimogene laherparepvec
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
  • Approved for the treatment of unresectable metastatic melanoma in line with NICE and NHS England Commissioning Policy (SSC1679).
 
Link  NICE TA410: Talimogene laherparepvec for treating unresectable metastatic melanoma
   
Venetoclax
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
  • Approved for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) in the presence of 17p deletion or TP53 mutations, and who are unsuitable for or have failed a B-cell receptor pathway inhibitor; and for the treatment of adult patients with CLL in the absence of 17p deletion ot TP53  mutation, and who are unsuitable for or have failed both chemo-immunotherapy and a B-cell receptor pathway inhibitor in line with MHRA Early Access to Medicines Scientific Opinion.
 
Link  Early Access to Medicines Scientific Opinion - Public Assessment Report
   
Picibanil
View adult BNF View SPC online View childrens BNF  Track Changes
Unlicensed Drug Unlicensed
Red
 
   
Streptozocin
View adult BNF View SPC online View childrens BNF  Track Changes
Unlicensed Drug Unlicensed
Red
  • Named patient supply only.
 
   
08.01.05  Expand sub section  Amsacrine
Cytotoxic Drug Amsacrine
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
 
   
08.01.05  Expand sub section  Arsenic trioxide
Cytotoxic Drug Arsenic Trioxide
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
  • NECDAG approved relapsed or refractory acute promyelocytic leukaemia (APL).
 
   
08.01.05  Expand sub section  Bevacizumab
08.01.05  Expand sub section  Bexarotene to top
08.01.05  Expand sub section  Bortezomib
Cytotoxic Drug Bortezomib
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
  • Approved for:
    • Relapsed multiple myeloma in line with in line with NICE.
    • Combination with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma in line with NICE. 
    • Induction therapy for multiple myeloma in line with NICE.
    • Treatment of adults with mantle cell lymphoma that has not been treated before, if haemotopoietic stem cell transplantation is not suitable, in line with NICE.

 
Link  NICE TA129: Multiple myeloma - bortezomib
Link  NICE TA228: Bortezomib and thalidomide for the first‑line treatment of multiple myeloma
Link  NICE TA311: Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation
Link  NICE TA370: Bortezomib for previously untreated mantle cell lymphoma
   
08.01.05  Expand sub section  Brentuximab vedotin
Brentuximab vedotin (Adcetris®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
High Cost Medicine
  • 50mg powder for concentrate for solution for infusion
  • Approved for the treatment of relapsed or refractory systemic anaplastic large cell lymphoma in line with NICE and NHS England Commissioning Policy.
  • Approved for the treatment of CD30-positive Hodgkin lymphoma in patients:
    • if they have already had autologous stem cell transplant
    • if they have already had at least 2 previous therapies when autologous stem cell transplant or multi-agent chemotherapy are not suitable. CDF

 

 
Link  NICE TA478 Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma
Link  NICE TA524 Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma
   
08.01.05  Expand sub section  Cetuximab
Cetuximab
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
  • Approved for the first-line treatment of metastatic colorectal cancer in combination with FOLFOX in line with NICE (monotherapy or combination chemotherapy is not recommended for the treatment of people with metastatic colorectal cancer that has progressed after first-line chemotherapy -  as per NICE). 
  • NECDAG approved for K-RAS wild type metastatic colorectal cancer; second line use in combination with chemotherapy in patients that have progressed on previous chemotherapy; third line use as a single agent in patients who have failed oxaliplatin- and irinotecan based therapy and who are intolerant to irinotecan. 
  • Approved for locally advanced squamous cell carcinoma of the head and neck in line with NICE. 
  • Approved for previously untreated metastatic colorectal cancer in line with NICE.
  • Approved for the treatment of metastatic and/or recurrent squamous cell carcinoma of the head and neck (oral cavity only) in line with NICE and NHS England Commissioning Policy
  • Note: cetuximab is not approved in combination with platinum-based chemotherapy for recurrent and/or metastatic squamous cell cancer of the head and neck as per NICE.
 
Link  NICE TA145: Cetuximab for the treatment of locally advanced squamous cell cancer of the head and neck
Link  NICE TA176: Cetuximab for the first-line treatment of metastatic colorectal cancer
Link  NICE TA242: Cetuximab for the treatment of metastatic colorectal cancer after first-line chemotherapy: monotherapy or combination chemotherapy
Link  NICE TA439 Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
Link  NICE TA473 Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck (oral cavity)
   
08.01.05  Expand sub section  Crisantaspase
08.01.05  Expand sub section  Dacarbazine and Temozolomide to top
Cytotoxic Drug Dacarbazine
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
 
   
Cytotoxic Drug Temozolomide
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
  • Approved for the treatment of recurrent malignant glioma in line with NICE.
  • Approved for newly diagnosed glioblastoma multiforme (GBM) in line with NICE.
 
Link  NICE TA121: Glioma (newly diagnosed and high grade)
Link  NICE TA23: Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer)
   
08.01.05  Expand sub section  Erlotinib
Erlotinib
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
  • Also approved for second line use, as an alternative to docetaxel, in NSCLC in line with NICE.
  • Monotherapy not approved for maintenance after platinum chemotherapy in advanced or metastatic NSCLC NICE.
  • Approved for the treatment of locally advanced or metastatic nonsmall-cell lung cancer that has already been treated with non-targetted chemotherapy because of delayed confirmation of epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation status if; their cancer tests positive for EGFR-TK mutation; it is not know if the cancer is EGFR-TK mutation- positive because of problems with the test, and the cancer is very likely to be EGFR-TK mutation-positive and it responds to the first 2 cycles of treatment with erlotinib - in line with NICE.
 
Link  NICE TA227: Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer
Link  NICE TA258: Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer
Link  NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
   
08.01.05  Expand sub section  Hydroxycarbamide
Cytotoxic Drug Hydroxycarbamide
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
  • 100mg tablets
  • 500mg capsules
  • 500mg in 5ml suspension (unlicensedunlicensed) is also approved
 
   
08.01.05  Expand sub section  Imatinab
08.01.05  Expand sub section  Ipilimumab
Ipilimumab
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
  • Approved for previously treated advanced melanoma in line with NICE.
  • Approved for previously untreated advanced melanoma in line with NICE.

 
Link  NICE TA268: Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma
Link  NICE TA319: Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma
Link  NICE TA357: Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab
Link  NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma
   
08.01.05  Expand sub section  Mitotane to top
Mitotane
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
 
   
08.01.05  Expand sub section  Panitumumab
Panitumumab (Vectibix®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
  • Approved for previously untreated metastatic colorectal cancer in line with NICE.
 
Link  NICE TA439 Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
   
08.01.05  Expand sub section  Pentostatin
Cytotoxic Drug Pentostatin (Nipent®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
 
   
08.01.05  Expand sub section  Platinum compounds
Cytotoxic Drug Carboplatin
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
 
   
Cytotoxic Drug Cisplatin
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
 
   
Cytotoxic Drug Oxaliplatin
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
  • Approved for Dukes C colon cancer in combination with 5-fluorouracil
    and folinic acid in line with NICE.
  • Approved for advanced and metastatic colorectal cancer in line with NICE.
 
Link  NICE TA100: Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes’ C) colon cancer
   
08.01.05  Expand sub section  Porfimer sodium and temoporfin
08.01.05  Expand sub section  Procarbazine to top
Cytotoxic Drug Procarbazine
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
 
   
08.01.05  Expand sub section  Protein kinase inhibitors
Afatinib
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
NHS England
  • Approved as a possible treatment for adults with locally advanced or metastatic non-small-cell lung cancer if their cancer tests positive for the epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation and they have not had an EGFR-TK inhibitor before NICE and additional NHS England criteria.
 
Link  NICE TA310: Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer
   
Axitinib
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
NHS England
  • Approved as treatment for adults with advanced renal cell carcinoma when tyrosine kinase inhibitors or cytokines have not worked in line with NICE.
 
Link  NICE TA333: Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment
   
Bosutinib (Bosulif®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
NHS England
  • Approved as an option for the treatment of chronic, accelerated blast phase Philidephia chromosome positive chronic myeloid leukaemia in adults when they have previously had 1 or more tyrosine kinase inhibitor and imatinib, nilotinib and dasatanib are not appropriate in line with NICE.
 
Link  NICE TA401: Bosutinib for previously treated chronic myeloid leukaemia
   
Cabozantinib (Cometriq®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
NHS England
  • Approved for use in the treatment of renal cell carcinoma in line with NICE and NHS England Commissioning Policy
  • Approved for the treatment of medullary thyroid cancer in line with NICE and NHS England Commissioning Policy
 
Link  NICE TA463 Cabozantinib for previously treated advanced renal cell carcinoma
Link  NICE TA516: Cabozantinib for treating medullary thyroid cancer
   
Ceritinib
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
NHS England
  • Approved for use in previously treated anaplastic lymphoma kinase positive non-small-cell-lung cancer in line with NICE and NHS England Commissioning Policy.
  • Approved for untreated ALK-positive non-small-cell lung cancer in line with NICE and NHS England Commissioning Policy
 
Link  NICE TA395: Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer
Link  NICE TA500: Ceritinib for untreated ALK-positive non-small-cell lung cancer
   
Crizotinib
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
  • Approved in accordance with NICE and NHS England Commissioning Policy.
 
Link  NICE TA406: Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
Link  NICE TA422: Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
   
Dabrafenib  (Tafinlar®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
NHS England
  • Approved for the treatment of unresectable or metastatic BRAF V600 mutation-positive melanoma in line with NICE 
 
Link  NICE TA321: Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma
Link  NICE TA396: Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma
   
Dasatinib (Sprycel®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
  • Approved for use in accordance with NICE and NHS Commissioning Policy
 
Link  NICE TA241: CML where treatment with imatinib has failed
Link  NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Link  NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
   
Everolimus (Afinitor®, Votubia®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
  • 2.5mg, 5mg & 10mg tablets (Votubia®)
    • Approved for the treatment of angiomyolipomas associated with tuberous sclerosis in accordnace with NHS England Commissioning Policy.
    • Approved for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in accordnace line with NHS England Commissioning Policy.

  • 5mg & 10mg tablets (Afinitor®)
    • Approved, in combination with exemestane, for the treatment of advanced human epidermal growth factor receptor 2 (HER2)-negative, hormone-receptor-positive breast cancer in postmenopausal women in accordance with NICE.
    • Approved for the treatment of advanced breast cancer after endocrine therapy in line with NICE.
    • Approved for the treatment of advanced renal cell carcinoma after previous treatment in line with NICE.
    • Approved for the treatment of unresectable or metastatic neuroendocrine tumours in people with progressive disease in line with NICE and NHS England Commissioning Policy

 
Link  Clinical Commissioning Policy Statement: Everolimus (Votubia®) for treatment of angiomyolipomas associated with tuberous sclerosis
Link  Clinical Commissioning Policy: Everolimus for subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex
Link  NICE TA421: Everolimus with exemestane for treating advanced breast cancer after endocrine therapy
Link  NICE TA432: Everolimus (Afinitor) for advanced renal cell carcinoma after previous treatment
Link  NICE TA449 Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
Link  NICE TA219: Everolimus for the second-line treatment of advanced renal cell carcinoma (Superceded by NICE TA432)
   
Gefitinib
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
  • Approved for first line use in locally advanced or metastatic NSCLC in line with NICE.
 
Link  NICE TA192: Lung cancer (non-small-cell, first line) - gefitinib
Link  NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
   
Ibrutinib (Imbruvica®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
NHS England
  • Approved for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation in line with NICE and NHS Commissioning Policy.
  • Approved for treating relapsed or refractory mantle cell lymphoma in line with NICE and NHS England Commissioning Policy if:
    • they have had only 1 previous line of therapy
 
Link  NICE TA429: Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation
Link  NICE TA502: Ibrutinib for treating relapsed or refractory mantle cell lymphoma
   
Imatinib
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
NHS England
  • Approved for the first-line management of people with KIT (CD117)- positive unresectable and/or KIT (CD117)-positive metastatic gastrointestinal stromal tumours (GISTs) in line with NICE. 
  • Approved for the adjuvant treatment of gastrointestinal stromal tumours (GISTs) after surgery when there is a high risk relapse of tumour NICE. 
  • Approved for Philadelphia-chromosome-positive CML in the accelerated phase or with blast crisis in line with NICE.
  • A standard-dose imatinib is recommended as an option for the first-line treatment of adults with chronic phase Philadelphia-chromosomepositive CML in line with NICE.
 
Link  NICE TA209: Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours
Link  NICE TA326: Imatinib for the adjuvant treatment of gastrointestinal stromal tumours
Link  NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Link  NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
   
Lapatinib
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
 
Link  NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer
   
Lenvatinib (Kisplyx®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
NHS England
  • 4mg & 10mg capsules
  • Approved with everolimus for previously treated advanced renal cell carcinoma in accordance with NICE
 
Link  NICE TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma
   
Nintedanib
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
  • Approved for the treatment of locally advanced, metastatic or locally recurrent non-small-cell lung cancer who have previously been treated been with first-line chemotherapy in accordance with NICE.
  • Approved for treating idiopathic pumonary fibrosis in line with NICE
 
Link  NICE TA347: Recurrent non-small-cell lung cancer
Link  NICE TA379: Nintedanib for treating idiopathic pulmonary fibrosis
   
Pazopanib
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
  • Approved for advanced renal cell carcinoma in line with NICE
 
Link  NICE TA215: Pazopanib in renal cell cancer
   
Ponatinib (Iclusig®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
  • 15mg, 30mg & 45mg film-coated tablets
  • Approved for the treatment of chronic myeloid leukaemia and acute lymphoblastic leukaemia in line with NICE and NHS England Commissioning Policy
 
Link  NICE TA451 Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia
   
Regorafenib (Stivarga® )
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
  • 40mg tablets
  • Approved for treating unresectable or metastatic gastrointestinal stromal tumours in adults whose disease has progressed on, or who are intolerant to, prior treatment with imatinib and sunitinib in line with NICE and NHS England Commissioning Policy (Cancer Drug Fund until 13th February 2018)
 
Link  NICE TA 488: Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours
   
Ruxolitinib
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
  • Approved for the treatment of disease-related splenomegaly or symptoms in adults with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemiaa myelofibrosis, only in people with intermediate-2 or high-risk disease in line with NICE.
 
Link  NICE TA386: Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis
   
Sorafenib (Nexavar®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
  • 200mg tablets
  • Approved for treatment of advanced hepatocellular carcinoma only for people with Child-Pugh grade A liver impairment in line with NICE and NHS Commissioning Policy
 
Link  NICE TA474 Sorafenib for treating advanced hepatocellular carcinoma
   
Sunitinib
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
NHS England
  • Approved for gastrointestinal stromal tumours (GISTs) in line with NICE. 
  • Approved for advanced and/or metastatic renal cell carcinoma in line with NICE.
  • Sunitinib not approved for second line use in advanced and/or metastatic renal cell carcinoma NICE.
  • Approved for the treatment of unresectable or metastatic neuroendocrine tumours in people with progressive disease in line with NICE and NHS England Commissioning Policy
 
Link  NICE TA169: Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma
Link  NICE TA179: Sunitinib for the treatment of gastrointestinal stromal tumours
Link  NICE TA449 Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
   
Trametinib
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
NHS England
  • Approved in combination with dabrafenib for the treatment of unresectable or metastatic melanoma in line with NICE and NHS England Commissioning Policy.
 
Link  NICE TA396: Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma
   
upoNilotinib
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
NHS England
  • Approved for the first-line treatment of adults with chronic phase Philadelphia-chromosome-positive CML in line with NICE and NHS Commissioning Policy
 
Link  NICE TA241: Dasatinib, nilotinib and high dose imatinib for CML
Link  NICE TA251: Dasatinib, nilotinib and imatinib for first line treatment of CML
Link  NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Link  NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
   
Vemurafenib
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
  • Approved melanoma (BRAF V600 mutation positive, unresectable metastatic) in line with NICE.
 
Link  NICE TA269: Vemurafenib for treating malignant melanoma
Link  NICE TA414: Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma
   
08.01.05  Expand sub section  Taxanes
Cytotoxic Drug Cabazitaxel
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
  • Approved for the treatment of hormone relapsed metastatic prostate cancer treated with with docetaxel in line with NICE.
 
Link  NICE TA391: Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel
   
Cytotoxic Drug Docetaxel
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
  • Approved for early node-positive breast cancer in line with NICE. 
  • Approved for hormone refractory metastatic prostate cancer in line with NICE.
 
Link  NICE TA101: Docetaxel for the treatment of hormone-refractory metastatic prostate cancer
Link  NICE TA109: Docetaxel for the adjuvant treatment of early node-positive breast cancer
   
Cytotoxic Drug Paclitaxel
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
  • The following formulations are approved:
  • 30mg in 5ml, 100mg in 16.7ml, and 150mg in 25ml concentrate for preparing IV infusion.
  • Approved for the treatment of recurrent ovarian cancer in line with NICE.
 
Link  NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
   
Cytotoxic Drug Paclitaxel - Albumin Bound Formulation (Abraxane®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
  • Note: Abraxane® 5mg in 1ml powder for suspension for infusion is restricted for use within its current license for metastatic breast cancer patients who cannot tolerate standard taxanes. 
  • Approved in combination with a platinum-based compound or platinum-based therapy alone (cisplatin or carboplatin) for first line therapy in ovarian cancer in line with NICE.
  • Approved in combination with a platinum-based drug (carboplatin or cisplatin) for second-line (or subsequent) therapy in ovarian cancer in line with NICE
  • Approved metastatic breast cancer in line with NICE.
  • Abraxane is not recommended for the adjuvant treatment of women with early node-positive breast cancer NICE.
  • Approved in combination with gemcitabine for untreated metastatic pancreatic cancer in line with NICE and NHS England Commissioning Policy as of 5th December 2017
 
Link  NICE TA360: Pancreatic cancer - paclitaxel with gemcitabine
Link  NICE TA476 Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer
   
08.01.05  Expand sub section  Topoisomerase I inhibitors
Cytotoxic Drug Irinotecan Hydrochloride
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
 
   
Cytotoxic Drug Topotecan
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
  • Approved for relapsed NSCLC in line with NICE.
  • Approved for recurrent or stage IVB cervical cancer in line with NICE.
  • Approved for second-line (or subsequent) treatment in advanced ovarian cancer in line with NICE.
  • Approved for the treatment of recurrent ovarian cancer in line with NICE.
 
Link  NICE TA183: Topotecan for the treatment of recurrent and stage IVB cervical cancer
Link  NICE TA184: Topotecan for the treatment of relapsed small-cell lung cancer
Link  NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
   
08.01.05  Expand sub section  Trabectedin
Cytotoxic Drug Trabectedin
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red

Approved for the treatment of recurrent ovarian cancer in line with NICE.

 
Link  NICE TA185: Soft tissue sarcoma - trabectedin
Link  NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
   
08.01.05  Expand sub section  Trastuzumab to top
Pertuzumab (Perjeta®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
  • Approved for the neoadjuvant treatment of HER2-positive breast cancer in line with NICE and NHS Commissioning Policy
  • Approved with trastuzumab and docetaxel for treating HER2-positive breast cancer in line with NICE and NHS Commissioning Policy
 
Link  NICE TA424: Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer
Link  NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer
   
Trastuzumab
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
  • Approved for metastatic or locally advanced inoperable gastric cancers in line with NICE.
  • Approved for early stage HER2-positive breast cancer in line with NICE.
  • Approved for advanced HER2-positive breast cancer in line with NICE.
  • Note: trastuzumab is not recommended in combination with an aromatase inhibitor for the first-line treatment in postmenopausal women with metastatic hormonereceptor- positive breast cancer that overexpresses HER2 - in line with NICE.
  • Trastuzumab 600mg subcutaneous injection is approved by NHS England for HER2-positive breast cancer in line with NECN guidance.
 
Link  NICE TA208: Gastric cancer (HER2-positive metastatic) - trastuzumab
Link  NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer
Link  NICE TA34: Breast cancer - trastuzumab
   
Cytotoxic Drug Trastuzumab emtansine (Kadcyla®)
(S/C injection)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
  • 100mg & 160mg powder for concentrate for solution for infusion
  • Approved for the treatment of HER2-positive advanced breast cancer after trastuzumab and a taxane in line with NICE and NHS England Commissioning Policy
 
Link  NICE TA458 Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane
   
08.01.05  Expand sub section  Tretinoin
Tretinoin
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
 
   
08.01.05  Expand sub section  Vismodegib
 ....
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Red

Drugs for hospital use only. The responsibility for initiation and monitoring treatment should rest with an appropriate hospital clinician and the drug should be supplied through the hospital throughout the duration of treatment. In some very exceptional circumstances (e.g. due to distance from the hospital, storage, supply or mobility/transport problems) it may be appropriate for the GP to be asked to prescribe a Red drug. This should be negotiated on an individual patient basis and should only be done with the GP’s prior informed agreement where the roles of the GP and hospital services are clearly defined and agreed. The GP should not feel under pressure to prescribe in these circumstances.   

Amber

Drugs initiated by hospital specialist, but where continuing treatment by GPs may be appropriate under a shared care arrangement. The specialist should send the GP a copy of the shared care agreement to sign. The GP should sign the shared care agreement, or indicate they do not want to be part of such an agreement, and return a copy back to the specialist. Shared care guidelines are available or are being developed for most of the drugs listed as Amber. If no shared care guideline is available, the hospital specialist should provide the patient’s GP with sufficient information and support to allow treatment to be continued and managed safely in primary care.  

Green plus

Drugs normally recommended or initiated by hospital specialist, but where the provision of an information leaflet may be appropriate to facilitate continuing treatment by GPs. Many of these information sheets are in the process of development.  

Green

Drugs where prescribing by GPs is appropriate. Drugs not classified as Red, Amber or Green Plus (formerly blue in North of Tyne) are generally classified as ‘Green’ by default. The Green drugs listed here include those products normally initiated by hospital specialists where there was a need for discussion and debate as to the category in which they should be placed.  

netFormulary